https://pubmed.ncbi.nlm.nih.gov/26044954/
Clinical Trial
Reference: Koizumi T, Tsushima K, Tanabe T, et al. Bronchoscopy-guided cooled radiofrequency ablation as a novel intervention therapy for peripheral lung cancer. Respiration. 2015;90(1):47-55.
Background: This is a prospective study evaluating the safety and feasibility of bronchoscopy-guided, cooled radiofrequency ablation (RFA) of inoperable NSCLC.
PICO:
Population –
- 20 patients with T1-2aN0M0 NSCLC who were inoperable or refused surgery
Intervention –
- 23 lesions were bronchoscopically treated with RFA under CT-guidance
- Median tumor size was 24 mm (range 12-45 mm)
Comparison –
- None
Outcome –
- 82.6% local tumor control rate (tumor decreased or stable in size)
- Median progression free survival was 35 months
- 5-year overall survival was 61.5%
- Complications were seen in three patients who presented with acute ablation-related reactions. These patients required hospitalization and improved with conservative management
Take home: Bronchoscopic RFA for early-stage lung cancer is feasible and safe. This may be considered in select patients who are not candidates for surgical resection or XRT.
